---
title: SICAPv2 Prostate Histopathology Benchmark
url: https://www.emergentmind.com/topics/sicapv2
type: topic
---

# SICAPv2 Prostate Histopathology Benchmark

SICAPv2 is a prostate histopathology benchmark built around H\&E-stained biopsy whole-slide images and Gleason-grade annotations. In its foundational description, it extends the earlier SICAP resource and couples whole-slide Gleason scoring with local Gleason pattern annotations and explicit cribriform markings, thereby supporting patch-level grading, cribriform detection, and biopsy-level score prediction within a single corpus [2105.10490]. Subsequent work has reused SICAPv2 under multiple task formulations—including four-class patch classification, binary benign–malignant safety analysis, five-class weakly supervised ISUP grading, CBMIR retrieval, and multi-class segmentation—so the name denotes both a source dataset and a family of derived experimental instantiations in computational prostate pathology [2605.02544][2604.12693][2210.17013].

## 1. Foundational dataset and reported corpus structure

The original SICAPv2 description reports **155 biopsies from 95 patients**, digitized as WSIs, with a total of **182 WSIs** because some patients contribute more than one biopsy [2105.10490]. At the WSI level, the same source gives the following counts by primary Gleason grade: **NC: 37**, **GG3: 60**, **GG4: 69**, and **GG5: 16**, for **182 WSIs** in total [2105.10490]. The images are H\&E stained prostate needle biopsies scanned with a **Ventana iScan Coreo** at **\(40\times\)** and then **down-sampled to \(10\times\)** for computational processing [2105.10490].

In the original end-to-end grading pipeline, the downsampled WSIs are tiled into **\(512 \times 512\)** patches with **50\% overlap** [2105.10490]. After preprocessing and selection, the patch-level composition is reported as **10,340 patches**: **4,417 NC**, **1,636 GG3**, **3,622 GG4**, and **665 GG5**; within GG4, **763 patches** are annotated as cribriform [2105.10490]. A later classification study using SICAPv2 reports the same four-class patch count of **10,340**, with **4417 benign**, **1636 grade 3**, **3622 grade 4**, and **665 grade 5** patches, extracted as **\(512 \times 512\)** tiles with **50\% overlap** from biopsy WSIs [2409.17122].

Other studies materialize SICAPv2 differently. In an attention-based MIL setting for WSI-level ISUP grading, SICAPv2 is described as **155 whole-slide images** of prostate biopsies, processed at **\(10\times\)** magnification, with an **average of 129 patches per WSI** and **\(256 \times 256\)** patch size [2210.17013]. A ViT-based classification study instead reports **11,836 image patches** distributed across **NC: 2,046**, **G3: 2,613**, **G4: 5,768**, and **G5: 1,409**, using an **80:20 split** [2508.11181]. A CBMIR study gives **10,330 patches** for retrieval experiments and uses **2,122** test patches as queries [2305.11728]. These parallel descriptions indicate that SICAPv2 is not used in a single canonical tensorized form; rather, studies derive task-specific sample sets from the same prostate biopsy collection.

## 2. Annotation schema and task-dependent label spaces

In the original dataset design, SICAPv2 combines **biopsy-level Gleason scores**, **pixel-level Gleason grade annotations**, and explicit **cribriform pattern** markings within Gleason grade 4 regions [2105.10490]. Patch-level labels are obtained from local annotations by assigning the **majority grade** when more than one annotated grade is present in a patch [2105.10490]. This supports the standard four-class patch label set
\[
\mathcal{Y} = \{\text{NC}, G3, G4, G5\},
\]
which is the label space used by multiple later classification and safety studies [2605.02544][2604.12693].

A recurrent secondary formulation is the clinically motivated binary superclass mapping
\[
S(y) =
\begin{cases}
0 & \text{if } y=\text{NC} \\
1 & \text{if } y \in \{\text{G3}, \text{G4}, \text{G5}\},
\end{cases}
\]
where **NC** is treated as **Benign / Safe / Non-Critical** and **G3–G5** as **Malignant / Critical** [2605.02544][2604.12693]. This mapping underlies recent work on clinically dangerous errors, where malignant-to-benign confusions are treated as high-risk failures and intra-malignant confusions are treated as lower-severity disagreements [2605.02544][2604.12693].

At the WSI level, label usage diverges. One MIL study formulates SICAPv2 as a **5-class ISUP grading** problem from WSI-level annotations, with each WSI treated as a bag of instances and no patch labels used during MIL training [2210.17013]. Another mixed-supervision MIL study instead treats slide-level Gleason grading as a **multi-label MIL classification task**, while deriving noisy instance labels from superpixels and limited pixel-level annotations [2206.12798]. A segmentation study notes that raw SICAPv2 provides **pixel-level annotations only for Gleason grades** and **does not provide explicit benign/background masks**, so benign masks are computationally derived before training a four-class segmentation model [2409.16205].

| Formulation | Label space | Representative studies |
|---|---|---|
| Patch classification | \( \{\text{NC}, G3, G4, G5\} \) | [2105.10490], [2409.17122], [2508.11181] |
| Safety superclass analysis | Benign vs Malignant | [2605.02544], [2604.12693] |
| WSI-level weak supervision | 5-class ISUP or slide-level Gleason labels | [2210.17013], [2206.12798] |
| Segmentation | Benign plus Gleason-pattern masks after preprocessing | [2409.16205] |

A common misconception is to treat SICAPv2 as having a single fixed label protocol. The literature shows instead that its annotation richness permits several compatible but non-identical task definitions.

## 3. Preprocessing conventions and experimental protocols

Preprocessing is highly task dependent. In the foundational system, WSIs are downsampled to **\(10\times\)**, tissue regions are identified with an **Otsu** tissue mask, patches with **less than 20\% tissue** are discarded, and cancerous-biopsy patches with no cancer annotations are removed [2105.10490]. This yields the patch-level training set used for end-to-end Gleason grading and cribriform detection [2105.10490].

Several later studies standardize input size at **\(224 \times 224\)**, but not identically. Risk-Calibrated Learning resizes all SICAPv2 images to **\(224 \times 224\)** and uses **random rotation, flipping, normalization**, together with AdamW, cosine annealing, and ImageNet-pretrained ResNet-50 or ViT-B16 backbones [2604.12693]. The targeted error-correction study also uses an ImageNet-pretrained **ResNet-50** in PyTorch with **Adam** and learning rate **0.001**, trained with standard multi-class cross-entropy over the four classes; its post-hoc GBDT modules operate only on the resulting softmax probability vectors [2605.02544]. By contrast, HistoViT applies only a lightweight pipeline—pixel scaling by **\(1/255\)**, channel permutation, resizing to **\(224 \times 224\)**, and batching with **batch size 32**—and explicitly states that it uses **no data augmentation** [2508.11181].

Weakly supervised and segmentation workflows rely on different representations. The mixed-supervision MIL Transformer filters blank areas, applies **stain normalization**, segments tissue into **SLIC superpixels**, and extracts **1280-dimensional MobileNetV2** features from **\(224 \times 224\)** crops around superpixel centroids [2206.12798]. EmbAugmenter processes SICAPv2 WSIs into **\(256 \times 256\)** patches, embeds them with ImageNet-pretrained **ResNet50** into **\(\mathbb{R}^{1024}\)**, and trains a DA-GAN on **48,552 \((\mathbf{h}_i,\tilde{\mathbf{h}}_i)\) pairs per fold** to synthesize embedding-space augmentations [2210.17013]. For segmentation, one study first performs **stain normalization**, then constructs a **Tissue-Graph** from **SLIC superpixels**, **MobileNetV2** features, and a **Region Adjacency Graph**, using that pipeline to derive benign masks absent from the original SICAPv2 labels [2409.16205].

This heterogeneity suggests that SICAPv2 functions less as a standardized preprocessed benchmark than as a histopathology source corpus instantiated through task-specific pipelines. Consequently, cross-paper metric comparison must be conditioned on preprocessing, label construction, and split protocol.

## 4. Major methodological uses in the literature

The original automatic grading system on SICAPv2 is built around **FSConv**, a shallow CNN trained from scratch for four-class patch-wise Gleason prediction, combined with a probability-map reconstruction step and an MLP that maps tissue-grade percentages to biopsy-level primary and secondary Gleason grades [2105.10490]. The same backbone is then fine-tuned for **cribriform pattern detection** inside GG4 [2105.10490]. This established SICAPv2 as a benchmark not only for patch classification but also for end-to-end biopsy scoring.

Weakly supervised learning on SICAPv2 has followed two principal lines. One line uses **attention-based MIL**, where each WSI is a bag and each patch is an instance; EmbAugmenter augments **patch embeddings** rather than pixels, using a generator–discriminator architecture in embedding space to reduce computational cost while maintaining MIL performance [2210.17013]. A second line uses **mixed supervision**, in which slide-level labels and superpixel-derived instance labels are jointly optimized within a Transformer. That model uses a learnable class token, instance tokens with 2D sinusoidal positional encoding, and a mixed objective
\[
L_{total}=\lambda L_{slide} + (1-\lambda)\sum_k L_{instance},
\]
with random masking of instances to reduce the effect of inaccurate local labels [2206.12798].

Recent classification studies evaluate more modern architectures directly on SICAPv2 patches. A comparative benchmark applies **YOLOv8x**, **ViT\_base\_patch16\_224\_in21k**, and **MedMamba / Vision Mamba** to four-class patch classification [2409.17122]. Another study fine-tunes **ViT-Base, patch16, 224** with a four-class linear head and standard cross-entropy, arguing that a relatively vanilla transformer already performs strongly on SICAPv2 under minimal preprocessing [2508.11181]. Segmentation work has likewise used SICAPv2 to compare **H-vmunet**, **SAM**, and **YOLOv8m**, with all models trained on processed multi-class segmentation maps rather than raw Gleason-only masks [2409.16205].

Safety-aware learning has become a separate methodological theme. **Risk-Calibrated Learning** introduces a confusion-aware severity matrix \( \mathbf{M} \) over the four SICAPv2 classes, with **\(\alpha=5\)** for benign-to-malignant confusions and **\(\beta=20\)** for malignant-to-benign confusions, so that fatal false negatives are penalized more heavily than intra-malignant confusions [2604.12693]. A complementary post-hoc approach applies a **dual-classifier GBDT pipeline** to the ResNet-50 softmax outputs: one GBDT predicts whether a base prediction is correct, and a second predicts whether an error is **human-like** or **non-human**, with only predicted non-human errors being corrected by a forced superclass flip [2605.02544]. A related robustness line uses **Uncertainty-Aware Multi-Expert Knowledge Distillation**, aligning shallow and compact features and weighting decoupled distillation terms by expert uncertainty under source-imbalanced and target-imbalanced SICAPv2 settings [2505.00592].

## 5. Reported empirical performance across tasks

The original SICAPv2 end-to-end system reports **patch-level quadratic Cohen’s kappa of 0.77** on the held-out test subset for four-class Gleason grading, **AUC of 0.82** for cribriform pattern detection, and **quadratic Cohen’s kappa of 0.81** for biopsy-level Gleason scoring [2105.10490]. Within that work, the shallow **FSConv + GMP** configuration is emphasized because it reaches performance comparable to or better than fine-tuned state-of-the-art architectures while using far fewer trainable parameters [2105.10490].

Mixed-supervision MIL achieves stronger slide-level metrics. The Transformer-based model with spatial encoding and **50\% masking** reports **macro AUC \(0.9429 \pm 0.0094\)** on SICAPv2, exceeding both slide-only and prior mixed-supervision baselines in that evaluation protocol [2206.12798]. In another WSI-level MIL setting, EmbAugmenter improves on no augmentation and approaches patch-space augmentation: **no augmentation** gives **46.5 \(\{22.4\}\)** accuracy, **patch augmentation** gives **52.3 \(\{10.8\}\)**, and **EmbAugmenter (Ind)** also gives **52.3 \(\{9.0\}\)**, while embedding-space augmentation is reported to be **more than 300×** faster computationally than pixel-space augmentation [2210.17013].

Patch-level architectural comparisons vary sharply with setup. On the four-class classification benchmark using **10,340** patches, **MedMamba** reports **Precision 64.61**, **Recall 58.23**, **F1-score 61.25**, and **Accuracy 69.98**, compared with **ViT Accuracy 66.02** and **YOLO Accuracy 64.70** [2409.17122]. In the ViT-only HistoViT study, the reported SICAPv2 results are much higher—**Accuracy 96.92\%**, **Precision 96.91\%**, **Recall 96.92\%**, and **AUC 99.71**—under that paper’s own patch set and split protocol [2508.11181]. These numbers should not be read as a single leaderboard because the underlying sample counts, splits, and preprocessing are not the same across papers.

SICAPv2 has also been used beyond classification. For segmentation, **H-vmunet** reports **DSC (F1) \(0.68 \pm 0.034\)**, **Precision \(0.68 \pm 0.047\)**, and **Recall \(0.68 \pm 0.031\)** on SICAPv2, exceeding **SAM** and **YoloS** in that study [2409.16205]. For retrieval, the unsupervised CAE-based UCBMIR system reports **top-5 recall 80\%** under its first evaluation protocol and **precision 70\%** under its second protocol on SICAPv2, while using a **200-dimensional** latent representation learned without Gleason labels during feature learning [2305.11728].

## 6. Safety, robustness, and unresolved issues

SICAPv2 has recently become a benchmark for clinically weighted error analysis. In Risk-Calibrated Learning, the primary safety metric is the **Critical Error Rate (CER)**, defined as the proportion of malignant samples misclassified as benign. On SICAPv2, with **ResNet-50**, **Focal Loss** yields **CER 9.07\%**, **F1-Macro 0.561**, and **Accuracy 63.6\%**, whereas **RCL-Proposed** yields **CER 6.23\%**, **F1-Macro 0.599**, and **Accuracy 69.3\%**; with **ViT-B16**, RCL reduces **CER from 10.69\% to 0.81\%** but also reduces **F1-Macro from 0.666 to 0.436** and **Accuracy from 71.1\% to 57.8\%** [2604.12693]. The SICAPv2 results therefore illustrate both a strong safety gain and a possible safety–accuracy trade-off, depending on architecture.

The post-hoc targeted error-correction framework studies a different safety notion: the rate of benign–malignant superclass confusions. On SICAPv2, the base ResNet-50 has **class accuracy 68.43\%**, **super-class accuracy 91.00\%**, and **191 non-human errors** among **2,122** test patches; after the dual-GBDT pipeline and superclass-flip policy, these become **class accuracy 69.18\%**, **super-class accuracy 92.13\%**, and **167 non-human errors**, corresponding to a **12.57\% reduction** in dangerous non-human errors [2605.02544]. The same study reports **0.1 ms** per-image overhead and **1.70\%** relative latency overhead on SICAPv2, indicating low post-hoc deployment cost [2605.02544].

Imbalance and domain shift are additional recurrent concerns. UMKD explicitly notes that, in SICAPv2, **stage III prostate cancer samples constitute 8\% of the cohort**, and reports state-of-the-art results in both source-imbalanced and target-imbalanced scenarios: in the source-imbalanced setting, **OA 91.02\%**, **mAcc 90.23\%**, **F1 90.94\%**, **MAE 0.1294**; in the target-imbalanced setting, **OA 91.75\%**, **mAcc 90.72\%**, **F1 91.72\%**, **MAE 0.1199** [2505.00592]. Other papers emphasize related limitations: limited and partly inaccurate instance labels in mixed-supervision MIL [2206.12798], lack of explicit benign masks in raw segmentation annotations [2409.16205], and clinically significant inter-observer variability in Gleason grading and cribriform recognition [2105.10490].

A persistent interpretive issue is that SICAPv2 supports multiple valid benchmark constructions but not a universally standardized one. Reported corpus sizes, split rules, patch definitions, and label abstractions differ substantially across studies. This suggests that direct method ranking without harmonized protocol is methodologically unsafe. At the same time, the breadth of these uses explains the benchmark’s continuing importance: SICAPv2 remains one of the few prostate pathology resources simultaneously used for patch classification, slide-level weak supervision, segmentation, retrieval, safety-aware optimization, and post-hoc reliability correction [2105.10490][2605.02544].

Source: https://www.emergentmind.com/topics/sicapv2